Abstract
In the last few years the advent of targeted therapies against oncogenic drivers significantly improved the survival of non small cell lung cancer (NSCLC) patients with a favourable toxicity profile. Therefore, genetic testing, including at least EGFR mutations and ALK/ROS1 rearrangements, should be performed in all NSCLC patients (in particular with adenocarcinoma) who received a diagnosis of advanced disease. This review focuses on novel druggable oncogenic drivers, such as MET exon 14 mutations/MET amplification, RET fusions, BRAF V600E mutations, KRAS G12C mutations, NTRK rearrangements, and HER2 alterations.
Highlights
Frontiers in OncologyCitation: Tartarone A, Lapadula V, Di Micco C, Rossi G, Ottanelli C, Marini A, Giorgione R, Ferrari K, Catalano M, Voltolini L, Mini E and Roviello G (2021) Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer. Front. Oncol. 11:632256
The recently seen improvements in non small cell lung cancer (NSCLC) outcomes are mainly related to the advent in clinical practice of immunotherapy in non-oncogene driven cancers and of targeted therapies in tumours with druggable oncogenes
This review focuses on novel druggable oncogenic drivers, such as mesenchymal-epithelial transition (MET) exon 14 mutations/MET amplification, RET fusions, BRAF V600E mutations, Kirstein Rat Sarcoma viral oncogene homolog (KRAS) G12C mutations, Neurotrophic receptor tyrosine kinase (NTRK) rearrangements, and human epidermal growth factor receptor 2 (HER2) alterations
Summary
Citation: Tartarone A, Lapadula V, Di Micco C, Rossi G, Ottanelli C, Marini A, Giorgione R, Ferrari K, Catalano M, Voltolini L, Mini E and Roviello G (2021) Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer. Front. Oncol. 11:632256.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
